Inventor · disambiguated record
James A. Johnson
Also filed as: JOHNSON JAMES A · JOHNSON JAMES ANDREW
56 granted patents·12 pending applications·323 citations·filing 1998–2025
98Inventor score
Files withBRISTOL MYERS SQUIBB CO35UCB Biopharma SRL11UCB PHARMA SA6UCB BIOPHARMA SPRL5SALVATI MARK E3
Top patents by PatentIndex Score
68 records- 0194US6605599B1Epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Aug 12, 2003·90 cites·62 claims
- 0293US7915410B2Acyclic IKur inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Mar 29, 2011·20 cites·2 claims
- 0392US9822096B2Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 21, 2017·8 cites·20 claims
- 0491US8575184B2Quinazolines as potassium ion channel inhibitorsJOHNSON JAMES A·Filed 2010·Granted Nov 5, 2013·16 cites·40 claims
- 0589US9969728B2Tetrahydroimidazopyridine derivatives as modulators of TNF activityUCB BIOPHARMA SPRL·Filed 2014·Granted May 15, 2018·14 cites·7 claims
- 0688US10011594B24-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 3, 2018·4 cites·30 claims
- 0788US9458114B2Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 4, 2016·9 cites·18 claims
- 0888US8394822B2Thieno-pyridine derivatives as MEK inhibitorsHUTCHINGS MARTIN CLIVE·Filed 2012·Granted Mar 12, 2013·13 cites·20 claims
- 0987US7790770B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 7, 2010·10 cites·25 claims
- 1087US6878718B2Phenylalanine enamide derivativesCELLTECH R&D LTD·Filed 2002·Granted Apr 12, 2005·17 cites·8 claims
- 1186US9174974B2Macrocyclic factor VIIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Nov 3, 2015·5 cites·9 claims
- 1286US6320045B1Process for the reduction of oxiranyl epothilones to olefinic epothilonesBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Nov 20, 2001·38 cites·4 claims
- 1385US10906919B2Fused pentacyclic imidazole derivativesUCB Biopharma SRL·Filed 2018·Granted Feb 2, 2021·2 cites·10 claims
- 1485US7772232B2Quinazolinyl compounds as inhibitors of potassium channel functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 10, 2010·8 cites·4 claims
- 1585US7241755B2Epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jul 10, 2007·4 cites·13 claims
- 1684US10676460B2Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 9, 2020·1 cites·15 claims
- 1784US7888376B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·8 cites·17 claims
- 1884US2023322726A1Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1983US8283359B2Thieno-pyridine derivatives as MEK inhibitorsHUTCHINGS MARTIN CLIVE·Filed 2008·Granted Oct 9, 2012·6 cites·16 claims
- 2082US10202405B2Fused pentacyclic imidazole derivativesUCB BIOPHARMA SPRL·Filed 2015·Granted Feb 12, 2019·4 cites·11 claims
- 2182US7125899B2Epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Oct 24, 2006·8 cites·20 claims
- 2282US2025230144A1Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2381USRE41893EEpothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Oct 26, 2010·2 cites·73 claims
- 2481US7501437B2Phenylalanine enamide derivativesUCB PHARMA SA·Filed 2007·Granted Mar 10, 2009·3 cites·24 claims
- 2580US10106528B26-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 23, 2018·3 cites·58 claims
- 2680US7122556B2Phenylalanine enamide derivativesCELLTECH R&D LTD·Filed 2004·Granted Oct 17, 2006·9 cites·25 claims
- 2780US2025127795A1Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 2879US2023250105A1Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityUCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 2977US9550737B2TNF -α modulating benzimidazolesUCB BIOPHARMA SPRL·Filed 2013·Granted Jan 24, 2017·4 cites·10 claims
- 3077US8536327B2Epothilone derivativesVITE GREGORY D·Filed 2007·Granted Sep 17, 2013·1 cites·3 claims
- 3176US8921542B2Epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 30, 2014·1 cites·3 claims
- 3276US7645770B2Phenylalanine enamide derivativesUCB PHARMA SA·Filed 2008·Granted Jan 12, 2010·1 cites·21 claims
- 3376US2022324836A1Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3475US9309243B2Imidazopyridine derivatives as modulators of TNF activityUCB BIOPHARMA SPRL·Filed 2013·Granted Apr 12, 2016·4 cites·11 claims
- 3575US8357809B2Acyclic IKur inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2011·Granted Jan 22, 2013·2 cites·2 claims
- 3675US7786177B2Phenylalanine enamide derivativesUCB PHARMA SA·Filed 2009·Granted Aug 31, 2010·1 cites·23 claims
- 3775US7531549B2Phenylalanine enamide derivativesUCB PHARMA SA·Filed 2006·Granted May 12, 2009·1 cites·24 claims
- 3874US11008306B2Quinazolines as potassium ion channel inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted May 18, 2021·0 cites·5 claims
- 3972US8604051B2Thieno-pyridine derivatives as MEK inhibitorsUCB PHARMA SA·Filed 2013·Granted Dec 10, 2013·1 cites·20 claims
- 4072USRE41895EEpothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Oct 26, 2010·0 cites·96 claims
- 4171US8304403B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2010·Granted Nov 6, 2012·2 cites·17 claims
- 4270US2021252012A1Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityUCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 4369US2015080440A1Epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 4467US11912721B2Fused pentacyclic imidazole derivativesUCB Biopharma SRL·Filed 2020·Granted Feb 27, 2024·0 cites·16 claims
- 4567US10336739B24-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jul 2, 2019·0 cites·2 claims
- 4667US8350037B2Thieno-pyridine derivatives as MEK inhibitorsUCB PHARMA SA·Filed 2010·Granted Jan 8, 2013·1 cites·8 claims
- 4765US10980814B2Fused pentacyclic imidazole derivatives as modulators of TNF activityUCB Biopharma SRL·Filed 2018·Granted Apr 20, 2021·0 cites·6 claims
- 4865US10287299B2Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activityUCB BIOPHARMA SPRL·Filed 2016·Granted May 14, 2019·1 cites·6 claims
- 4964US2019263791A14-hydroxy-3-(heteroaryl)pyridine-2-one apj agonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 5059US11554122B2Fused pentacyclic imidazole derivatives as modulators of TNF activityUCB Biopharma SRL·Filed 2019·Granted Jan 17, 2023·0 cites·8 claims
Showing the top 50 of 68 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when James A. Johnson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →